We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Johnson and Johnson | NEO:JNJ | NEO | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.02 | 0.10% | 19.22 | 18.80 | 19.25 | 19.22 | 18.98 | 19.19 | 6,416 | 22:30:01 |
From Jan 2023 to Jan 2025
By Ben Glickman
Shares of Ambrx Biopharma surged Monday after the company agreed to be acquired by Johnson & Johnson for $2 billion in cash.
The stock was up 98% to $27.05 in morning trading. Shares have risen sixfold in the last year.
Johnson & Johnson will pay $28 a share, which Ambrx said represented a premium of 105% on the Jan. 5 closing price.
The deal is expected to have a value of $1.9 billion net of estimated cash required.
Ambryx is developing candidates for treating multiple types of cancer using a proprietary synthetic biotechnology platform.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
January 08, 2024 09:49 ET (14:49 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year Johnson and Johnson Chart |
1 Month Johnson and Johnson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
